CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Royalty Pharma Q3 2026 attributable net income falls 49% year over year to $145 million

By Public Technologies
  • Royalty Pharma's third-quarter 2026 net income attributable to shareholders fell 49% year over year to $145 million.
  • Total income and other revenues rose 13% year over year to $690 million.
  • A $150 million noncash impairment charge related to pelacarsen followed its Phase 3 trial's failure to meet the primary endpoint.
  • September's acquisition of a royalty interest in Zoryve from AstraZeneca cost $100 million upfront.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk